MDGL FY2025 SEC EDGAR DEF 14A #75 of 168 in industry

Madrigal Pharmaceuticals, Inc. CEO pay ratio

The CEO earned $19.0M in FY2025 against median worker pay of $403,403 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#75/168

Data updated August 2026

Subscribe to Madrigal Pharmaceuticals, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
47:1
Below Average (Scale: 0–1000:1)
CEO pay
$19.0M
Median worker
$403,403

Answer first

Madrigal Pharmaceuticals, Inc.'s FY2025 CEO total of $19.0M ranks #187 of 1,423 complete filings; its 47:1 pay ratio ranks #993. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $403,403. Industry placement uses the FY2025 SIC-28 peer cohort (# 75 of 168, 56th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#187
$19.0M of 1,423 FY2025
Ratio rank
#993
47:1 of 1,423
Industry pct
56th
above the industry median pay ratio

How Madrigal Pharmaceuticals, Inc. ranks nationally

Madrigal Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$18,959,941 Top 13% higher than 87% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). This entry sits in this band. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Madrigal Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($19.0M) against pay ratio (47:1) for Madrigal Pharmaceuticals, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7346514.710388126.41342973816471349.719512961.341.7:143.4:145:146.6:148.3:1CEO total payPay ratio (CEO : median worker)Madrigal Pharmaceuticals, Inc., CEO total pay: 18959941 · Pay ratio (CEO : median worker): 47:1Madrigal Pharmaceuticals, Inc.Adaptive Biotechnologies Corp, CEO total pay: 9147140 · Pay ratio (CEO : median worker): 47:1Adaptive Biotechnologies CorpCorcept Therapeutics Inc, CEO total pay: 15303551 · Pay ratio (CEO : median worker): 46:1Corcept Therapeutics IncAlnylam Pharmaceuticals, Inc., CEO total pay: 14984640 · Pay ratio (CEO : median worker): 48:1Alnylam Pharmaceuticals, Inc.Vaxcyte, Inc., CEO total pay: 14585904 · Pay ratio (CEO : median worker): 48:1Vaxcyte, Inc.
Madrigal Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Madrigal Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Madrigal Pharmaceuticals, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
47:1
FY2025
vs prior FY
+9:1
from FY2024 38:1
CEO $ YoY
+57%
$19.0M latest
Filings shown
5
FY2021–2025
Madrigal Pharmaceuticals, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $2.8M - $459,419 6:1 -
2022 $5.3M +92% $441,396 12:1 +6:1
2023 $32.6M +515% $479,000 68:1 +56:1
2024 $12.1M -63% $317,550 38:1 -30:1
2025 $19.0M +57% $403,403 47:1 +9:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1157601, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
47:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$19.0M
Companies in Industry
168
vs. Industry Median
Above
#75 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Madrigal Pharmaceuticals, Inc.: MODEST · PEAK pay ratio

Madrigal Pharmaceuticals, Inc.'s FY2025 CEO total $19.0M ranks #187 of 1,423 complete filings (higher third by dollars). the CEO earned 47× the median employee ($403,403) in FY2025.

Median employee $403,403 (ELITE-MED); MODEST · PEAK stamps put about 47 median-wage years per CEO year.

CEO Total Pay

$19.0M

FY2025 Summary Compensation, well above median

Pay Ratio

47:1

Below typical

Madrigal Pharmaceuticals, Inc. in the higher-dollar third

Madrigal Pharmaceuticals, Inc.'s FY2025 CEO total $19.0M ranks #187 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Madrigal Pharmaceuticals, Inc.'s $19.0M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #187 and ratio rank #993 split - treat 47:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$19.0M
Median Employee Pay
$403,403
Pay Ratio
47:1
Filing Date
2026-04-28

Company Info

Ticker
MDGL
CIK
1157601
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1157601, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Madrigal Pharmaceuticals, Inc.'s FY2025 CEO total $19.0M ranks #187 of 1,423 complete filings (higher third by dollars).

Read with Madrigal Pharmaceuticals, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · PEAK · ELITE-MED.

Marathon Petroleum Corp · PEAK

ABS(ceo_total_comp) peer at $19.0M (Δ $26K heavier vs Madrigal Pharmaceuticals, Inc.); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
Zoetis Inc. · PEAK

ABS(ceo_total_comp) peer at $19.0M (Δ $60K heavier vs Madrigal Pharmaceuticals, Inc.); STEEP · HIGH-MED vs this page's MODEST · PEAK · ELITE-MED.
Carnival Corp Ltd. · PEAK

ABS(ceo_total_comp) peer at $18.9M (Δ $72K lighter vs Madrigal Pharmaceuticals, Inc.); MEGA · LOW-MED vs this page's MODEST · PEAK · ELITE-MED.
Teva Pharmaceutical Industries Ltd · PEAK

ABS(ceo_total_comp) peer at $19.2M (Δ $209K heavier vs Madrigal Pharmaceuticals, Inc.); STEEP · HIGH-MED vs this page's MODEST · PEAK · ELITE-MED.
Adaptive Biotechnologies Corp (SIC 28 pole)

Adaptive Biotechnologies Corp stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Madrigal Pharmaceuticals, Inc.'s MODEST filing.
National dual ranks · #187/#993

Madrigal Pharmaceuticals, Inc.'s FY2025 package sits #187 by CEO dollars and #993 by ratio under PEAK · MODEST.
Ratio primer · MODEST

Madrigal Pharmaceuticals, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Madrigal Pharmaceuticals, Inc. (CIK 1157601), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.